Paul Bröckelmann
@broeckelmann.bsky.social
Physician Scientist in Cologne, interested in Hemato-Oncology, Lymphoma & Immunotherapy. Views are mine & no advise, repost/like no endorsement. COI: http://bit.ly/34MaLOt
Pinned
Great to see my Commentary entitled "Hodgkin lymphoma: Great progress but room for improvement" published in the current issue of Nature Reviews Clinical Oncology
@natrevclinonc.nature.com Open Access Link: shorturl.at/YHOAn
@natrevclinonc.nature.com Open Access Link: shorturl.at/YHOAn
Reposted by Paul Bröckelmann
RW outcomes CD19 CAR Burkitt
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
November 17, 2025 at 8:21 PM
RW outcomes CD19 CAR Burkitt
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org
November 13, 2025 at 8:36 PM
Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org
Very happy to share our new Blood Spotlight Review on patterns of immune-related toxicities with anti-PD1 first-line treatment of Hodgkin lymphoma and remaining uncertainties @bloodjournals.hematology.org: doi.org/10.1182/bloo... Congrats to GHSG Physician Christian Jaworek for spearheading this!
November 4, 2025 at 10:04 AM
Very happy to share our new Blood Spotlight Review on patterns of immune-related toxicities with anti-PD1 first-line treatment of Hodgkin lymphoma and remaining uncertainties @bloodjournals.hematology.org: doi.org/10.1182/bloo... Congrats to GHSG Physician Christian Jaworek for spearheading this!
Congrats @danielbachurski.bsky.social and everyone involved @uniklinikkoeln.bsky.social #CRC1530! Really great to see this exciting method and resulting mechanistic insights into immune remodelling in B-cell malignancies evolve over the last years and finally available as a Preprint.
Excited to share that TeLEV is now live! Our preprint introduces a new method to track #extracellularvesicle (EV) proteomes in single cells using advanced techniques. TeLEV reveals insights into an interleukin receptor triad and immune remodeling. Huge thanks to all collaborators! Preprint here:
Single recipient cell tracking of tellurium-labeled extracellular vesicle proteomes (TeLEV) identifies EV-driven immunomodulation
Extracellular vesicles (EVs) mediate tumor-immune cell communication by carrying protein cargo that can immediately modulate signaling and antigen presentation. Yet mapping the uptake of primary EV pr...
www.biorxiv.org
November 4, 2025 at 9:56 AM
Congrats @danielbachurski.bsky.social and everyone involved @uniklinikkoeln.bsky.social #CRC1530! Really great to see this exciting method and resulting mechanistic insights into immune remodelling in B-cell malignancies evolve over the last years and finally available as a Preprint.
Reposted by Paul Bröckelmann
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
November 4, 2025 at 9:53 AM
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Reposted by Paul Bröckelmann
Updated peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025–2026 season @nejm.org @jakescottmd.bsky.social @stanforddeptmed.bsky.social
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 | NEJM
Changes in the vaccine advisory process in the United States have disrupted immunization
guidance, which reinforces the need for independent evidence review to inform decisions
regarding immunizati...
www.nejm.org
October 29, 2025 at 9:44 PM
Updated peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025–2026 season @nejm.org @jakescottmd.bsky.social @stanforddeptmed.bsky.social
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Reposted by Paul Bröckelmann
A surprise bonus from COVID-19 vaccines: bolstering cancer treatment @science.org
Patients who got shots of mRNA before starting a type of cancer immunotherapy lived much longer
www.science.org/content/arti...
on @nature.com
www.nature.com/articles/s41...
Patients who got shots of mRNA before starting a type of cancer immunotherapy lived much longer
www.science.org/content/arti...
on @nature.com
www.nature.com/articles/s41...
A surprise bonus from COVID-19 vaccines: bolstering cancer treatment
Patients who got shots of mRNA before starting a type of cancer immunotherapy lived much longer
www.science.org
October 23, 2025 at 6:44 PM
A surprise bonus from COVID-19 vaccines: bolstering cancer treatment @science.org
Patients who got shots of mRNA before starting a type of cancer immunotherapy lived much longer
www.science.org/content/arti...
on @nature.com
www.nature.com/articles/s41...
Patients who got shots of mRNA before starting a type of cancer immunotherapy lived much longer
www.science.org/content/arti...
on @nature.com
www.nature.com/articles/s41...
Reposted by Paul Bröckelmann
Patient-centered and proportionate safety reporting in clinical trials is an EHA priority. Learn more about EHA's work in this recent HemaSphere Perspective: https://bit.ly/3JbBL1s
October 22, 2025 at 2:06 PM
Patient-centered and proportionate safety reporting in clinical trials is an EHA priority. Learn more about EHA's work in this recent HemaSphere Perspective: https://bit.ly/3JbBL1s
Reposted by Paul Bröckelmann
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
October 14, 2025 at 7:58 PM
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
Reposted by Paul Bröckelmann
A next-generation anti-CTLA-4 probody (folding the Fab fragment of the antibody in a tumor-associated protease-based manner) mitigates toxicity and enhances anti-tumor immunity in mice @natcomms.nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
October 10, 2025 at 4:03 PM
A next-generation anti-CTLA-4 probody (folding the Fab fragment of the antibody in a tumor-associated protease-based manner) mitigates toxicity and enhances anti-tumor immunity in mice @natcomms.nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Paul Bröckelmann
IFNγ-producing PD-1+ T cells are a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving immune checkpoint inhibitor therapy @lunduniversity.bsky.social
www.nature.com/articles/s44...
www.nature.com/articles/s44...
October 7, 2025 at 4:38 PM
IFNγ-producing PD-1+ T cells are a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving immune checkpoint inhibitor therapy @lunduniversity.bsky.social
www.nature.com/articles/s44...
www.nature.com/articles/s44...
Reposted by Paul Bröckelmann
Eomes controls the acquisition of regulatory and cytotoxic function in CD4+ T cells that are critical for limiting immune toxicity, while maintaining persistence and tumor control after immunotherapy @cp-immunity.bsky.social
www.cell.com/immunity/ful... @fredhutch.org
www.cell.com/immunity/ful... @fredhutch.org
October 2, 2025 at 4:55 PM
Eomes controls the acquisition of regulatory and cytotoxic function in CD4+ T cells that are critical for limiting immune toxicity, while maintaining persistence and tumor control after immunotherapy @cp-immunity.bsky.social
www.cell.com/immunity/ful... @fredhutch.org
www.cell.com/immunity/ful... @fredhutch.org
Reposted by Paul Bröckelmann
Cancer deaths expected to rise to over 18 million in 2050—an increase of nearly 75% from 2024, study forecasts.
Explore the data ▶️ tinyurl.com/5n7dfnws @ihmeuw.bsky.social #NCDs
Explore the data ▶️ tinyurl.com/5n7dfnws @ihmeuw.bsky.social #NCDs
September 25, 2025 at 3:04 PM
Cancer deaths expected to rise to over 18 million in 2050—an increase of nearly 75% from 2024, study forecasts.
Explore the data ▶️ tinyurl.com/5n7dfnws @ihmeuw.bsky.social #NCDs
Explore the data ▶️ tinyurl.com/5n7dfnws @ihmeuw.bsky.social #NCDs
Congrats to my colleagues @unicologne.bsky.social, @uniklinikkoeln.bsky.social and @mpiage.bsky.social on their exciting study revealing functional synapses between neurons and small cell lung cancer. Out today @nature.com
Following malignant transformation, small cell lung cancer cells hijack neuronal synaptic signaling to promote tumor growth @nature.com
@stanforduniversity.bsky.social
www.nature.com/articles/s41...
@unicologne.bsky.social www.nature.com/articles/s41...
@stanforduniversity.bsky.social
www.nature.com/articles/s41...
@unicologne.bsky.social www.nature.com/articles/s41...
September 10, 2025 at 4:48 PM
Congrats to my colleagues @unicologne.bsky.social, @uniklinikkoeln.bsky.social and @mpiage.bsky.social on their exciting study revealing functional synapses between neurons and small cell lung cancer. Out today @nature.com
Excited to share our preprint on the new HaJo cell line and robust systemic PDX in vivo model includin comprehensive characterization to enable further research in rare non-MCL B-cell lymphoma with CCND1 re-arrangement: www.biorxiv.org/content/10.1...
@mpiage.bsky.social @uniklinikkoeln.bsky.social
@mpiage.bsky.social @uniklinikkoeln.bsky.social
September 3, 2025 at 8:35 AM
Excited to share our preprint on the new HaJo cell line and robust systemic PDX in vivo model includin comprehensive characterization to enable further research in rare non-MCL B-cell lymphoma with CCND1 re-arrangement: www.biorxiv.org/content/10.1...
@mpiage.bsky.social @uniklinikkoeln.bsky.social
@mpiage.bsky.social @uniklinikkoeln.bsky.social
Reposted by Paul Bröckelmann
A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR T-cell therapy. Read the full case details: nej.md/41fYX4v
#MedSky #Hematology #Genetics
#MedSky #Hematology #Genetics
September 1, 2025 at 7:02 PM
A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR T-cell therapy. Read the full case details: nej.md/41fYX4v
#MedSky #Hematology #Genetics
#MedSky #Hematology #Genetics
Honoured to have contributed a @bloodjournals.hematology.org Commentary (doi.org/10.1182/bloo...) on a recent study by @drmiguelperales.bsky.social @mskcancercenter.bsky.social highlighting improved outcomes with alloSCT in r/r cHL after prior ICI exposure (doi.org/10.1182/bloo...)
August 26, 2025 at 1:11 PM
Honoured to have contributed a @bloodjournals.hematology.org Commentary (doi.org/10.1182/bloo...) on a recent study by @drmiguelperales.bsky.social @mskcancercenter.bsky.social highlighting improved outcomes with alloSCT in r/r cHL after prior ICI exposure (doi.org/10.1182/bloo...)
Longitudinal measurement of serum TARC shows rapid early cHL response to first-line nivolumab monotherapy and N-AVD. Potential to guide individualized immunotherapy? Great collaboration with W. Plattel @rug.nl now published @hemasphere-journal.bsky.social: onlinelibrary.wiley.com/doi/epdf/10....
August 26, 2025 at 1:03 PM
Longitudinal measurement of serum TARC shows rapid early cHL response to first-line nivolumab monotherapy and N-AVD. Potential to guide individualized immunotherapy? Great collaboration with W. Plattel @rug.nl now published @hemasphere-journal.bsky.social: onlinelibrary.wiley.com/doi/epdf/10....
Great to see the results of a joint NLG x GHSG academic phase 2 trial @hemasphere-journal.bsky.social: First-line treatment with B-CAP is feasible and effective in older patients with advanced-stage cHL, with improvement of most patient-reported HRQoL domains onlinelibrary.wiley.com/doi/10.1002/...
August 25, 2025 at 7:54 PM
Great to see the results of a joint NLG x GHSG academic phase 2 trial @hemasphere-journal.bsky.social: First-line treatment with B-CAP is feasible and effective in older patients with advanced-stage cHL, with improvement of most patient-reported HRQoL domains onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Paul Bröckelmann
📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines
🔗 buff.ly/2ZYJc2c
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines
🔗 buff.ly/2ZYJc2c
August 5, 2025 at 9:12 AM
📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines
🔗 buff.ly/2ZYJc2c
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines
🔗 buff.ly/2ZYJc2c
Reposted by Paul Bröckelmann
Review @cp-med.bsky.social
Immune-related adverse events associated with cancer immunotherapy
www.cell.com/med/abstract...
Immune-related adverse events associated with cancer immunotherapy
www.cell.com/med/abstract...
Immune-related adverse events associated with cancer immunotherapy
This review explores immune-related toxicities arising from the major immunotherapy
classes. By comparing mechanisms, risk factors, and management strategies across therapeutic
platforms, the authors ...
www.cell.com
August 1, 2025 at 3:01 PM
Review @cp-med.bsky.social
Immune-related adverse events associated with cancer immunotherapy
www.cell.com/med/abstract...
Immune-related adverse events associated with cancer immunotherapy
www.cell.com/med/abstract...
Reposted by Paul Bröckelmann
In a patient with pathogenic ZAP70 mutations and HPV19-integrated SCC, restoring T-cell receptor signaling by stem-cell transplantation resolved HPV-related disease, revealing a direct oncogenic role for β-HPV in immunodeficiency. Read the Brief Report: nej.md/4lTiTCC
#MedSky
#MedSky
July 30, 2025 at 9:40 PM
In a patient with pathogenic ZAP70 mutations and HPV19-integrated SCC, restoring T-cell receptor signaling by stem-cell transplantation resolved HPV-related disease, revealing a direct oncogenic role for β-HPV in immunodeficiency. Read the Brief Report: nej.md/4lTiTCC
#MedSky
#MedSky
Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social 🎉 Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options 🧵👀👇
July 24, 2025 at 3:31 PM
Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social 🎉 Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options 🧵👀👇
Reposted by Paul Bröckelmann
#NatMetabPicks | In Cancer Discovery @aacrjournals.bsky.social, L Zitvogel, C Bigenwald et al (@gustaveroussy.fr)
Oral supplementation with Akkermansia spp. Improves the efficacy of CAR-T cells against B cell lymphoma.
🧪
aacrjournals.org/cancerdiscov...
Oral supplementation with Akkermansia spp. Improves the efficacy of CAR-T cells against B cell lymphoma.
🧪
aacrjournals.org/cancerdiscov...
Gut microbiota modulation through Akkermansia spp. supplementation increases CAR-T cell potency
Abstract. This study investigates the clinical relevance of the gut microbiome at taxonomic and metabolic levels in anti-CD19 CAR-T cell therapy, both in patients and in a preclinical syngeneic tumor ...
aacrjournals.org
July 14, 2025 at 3:25 PM
#NatMetabPicks | In Cancer Discovery @aacrjournals.bsky.social, L Zitvogel, C Bigenwald et al (@gustaveroussy.fr)
Oral supplementation with Akkermansia spp. Improves the efficacy of CAR-T cells against B cell lymphoma.
🧪
aacrjournals.org/cancerdiscov...
Oral supplementation with Akkermansia spp. Improves the efficacy of CAR-T cells against B cell lymphoma.
🧪
aacrjournals.org/cancerdiscov...
Reposted by Paul Bröckelmann
By integrating multi-dimensional data with deep learning, a new method known as ImmuScope predicts both MHC-II presentation and T helper cell immunogenicity @natmachintell.nature.com
www.nature.com/articles/s42...
www.nature.com/articles/s42...
www.nature.com/articles/s42...
www.nature.com/articles/s42...
July 18, 2025 at 2:31 PM
By integrating multi-dimensional data with deep learning, a new method known as ImmuScope predicts both MHC-II presentation and T helper cell immunogenicity @natmachintell.nature.com
www.nature.com/articles/s42...
www.nature.com/articles/s42...
www.nature.com/articles/s42...
www.nature.com/articles/s42...